Prostate Cancer | Specialty

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

March 8th 2016

Researchers evaluate the role of magnetic resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

Vitamin D Could Serve as Biomarker for Aggressive Prostate Cancer

March 7th 2016

The level of vitamin D in a patient’s blood could serve as a biomarker for an aggressive form of prostate cancer, especially in men who are considering active surveillance for the disease.

Personalized Therapy Emerging for Patients With Prostate Cancer

March 6th 2016

Tomasz M. Beer, MD, FACP, discusses how having a deeper understanding of the genetic makeup of patients with castration-resistant prostate cancer would open the door to novel treatments, both monotherapy and combination regimens.

Dr. Turkbey on Sodium Fluoride PET Imaging for Prostate Cancer

March 3rd 2016

Ismail Baris Turkbey, MD, staff clinician in the Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, discusses sodium fluoride PET imaging for patients with prostate cancer.

Biomarker-Directed Galeterone Explored in Prostate Cancer Trial

February 24th 2016

Galeterone is being explored in the ARMOR 3-SV study, in which men with progressive metastatic disease who have received prior androgen deprivation therapy are randomized to receive either galeterone or enzalutamide.

Evidence Supports Earlier Use of Radium-223, Expert Says

February 24th 2016

Fred Saad, MD, discusses treatment with radium-223 in asymptomatic patients and potential combination regimens with the radiopharmaceutical in castration-resistant prostate cancer.

With Radium-223 Leading the Way, Use of Radiopharmaceuticals Continues to Evolve

February 24th 2016

Neal Shore, MD, discusses the evolution of radiopharmaceuticals, how radium-223 works, and its potential for use in combination with other agents.

FDA Agrees to Review Supplemental NDA for Enzalutamide in Metastatic Prostate Cancer

February 23rd 2016

The FDA has accepted, for review, a supplemental new drug application for enzalutamide (Xtandi) capsules in patients with metastatic castration-resistant prostate cancer that includes findings from the head-to-head studies, TERRAIN and STRIVE.

Dr. Emberton on Focal Therapy Techniques in Prostate Cancer

February 23rd 2016

Mark Emberton, MD, professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London Hospitals, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses techniques of focal therapy in patients with prostate cancer.

Dr. Saad on Expanded Access Program With Radium-223

February 23rd 2016

Fred Saad, MD, FRCSC, principal scientist, full professor, Department of Surgery, chair in Prostate Cancer Research, Université de Montréal, medical director, Interdisciplinary Urologic Oncology Group, head, Urologic Oncology, CHUM, discusses the expanded access program (EAP) of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

FDA Approval in Liposarcoma, Breakthrough Designations in mCRPC and AML, and More

February 5th 2016

Innovation, Education Critical to Optimizing Early Detection in Prostate Cancer

February 3rd 2016

E. David Crawford, MD, discusses his view of the current role for PSA testing in prostate cancer and the need for continued innovation and advancement with new screening technologies.

In a Crowded Field, High-Intensity Focused Ultrasound Stakes a Claim

February 2nd 2016

The landscape for the patient with localized prostate cancer is filled with both new and exciting treatments. With better methods to screen, improved imaging scans to determine physical location and extent of cancer, and even active surveillance, there are many options to consider.

“Hormone Holiday” Can Improve QoL for Select Patients With Prostate Cancer

February 1st 2016

Leonard G. Gomella, MD, discusses intermittent hormonal therapy for patients with prostate cancer as well as its benefits and challenges.

Genomic Classifier Refines Risk Calculation After Prostatectomy

February 1st 2016

Using a genomic classifier that identifies men who are at highest risk for developing metastasis after prostatectomy and salvage radiation therapy can help clinicians distinguish which patients would benefit from more aggressive follow-up therapy, according to recent research.

FDA Grants Olaparib Breakthrough Designation in mCRPC

January 28th 2016

Olaparib (Lynparza) has received an FDA breakthrough therapy designation as a treatment for patients with BRCA1/2 or ATM-mutated metastatic castration-resistant prostate cancer in those who have received a prior taxane-based chemotherapy and at least either hormonal agent enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Dr. Morris on Mechanism of Action for Radium-223

January 27th 2016

Michael Morris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the mechanism of action for radium-223 dichloride as a treatment for patients with prostate cancer.

Up to 12 Doses of Radium-223 Proven Safe in Bone-Metastatic Prostate Cancer

January 27th 2016

Retreatment with radium-223 dichloride (Xofigo) after initial therapy and progression was determined to be safe in patients with bone-metastatic castration-resistant prostate cancer.

Radium-223 Benefits Survival, Not Just for Palliative Care

January 25th 2016

Phillip J. Koo, MD, discusses the benefits of radium-223 and why he thinks it is time the use of the drug becomes more widespread for the treatment of mCRPC, and potentially other cancers.

Radiation/Immunotherapy Combos Slow to Gain Traction, But Have Potential in Prostate Cancer

January 20th 2016

Steven Finkelstein, MD, explains why radiation and immunotherapy may be an effective combination in prostate cancer.